• 22Apr

    old.jpg

    A new treatment that underwent clinical trial for a year has proven to be safe and helped reduce the progress of the disease. Researchers from Purdue University designed a molecule that inhibits the eventual formation of amyloid plaque in the brain, which causes the symptoms of Alzheimer’s. This is developed into a drug which was given to volunteers for clinical trial in 2007. The levels of protein amyloid beta is measured in plasma, and is considered a biomarker. Reduction of this protein indicates the effectiveness of the new drug. A second clinical trial is scheduled this year.

    Alzheimer’s disease shows its symptoms usually after the age of 60.

    (source)

Comments are closed.

Bad Behavior has blocked 41 access attempts in the last 7 days.